Gil is featured on a NeurologyToday post about donanemab and the next steps after positive results of the phase 3 trial.
Exciting times as Alzheimer's Disease treatments finally show clinical benefit and a modification in the disease course. Some points are raised about the future use of biomarkers (PET, CSF and/or plasma), side effects and the representativity of the population studied in the donanemab trial.
